Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in newly diagnosed diabetic patients

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 5, 2010, Pages 386-392

  Hernández, Cristina ^a,b   Zapata, Miguel A ^b   Losada, Eladio ^b   Villarroel, Marta ^b   García Ramírez, Marta ^a,b   García Arumí, José ^b   Simó, Rafael ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Diabetes; Flt 1; Insulin; Macular edema; Optical coherence tomography; Soluble VEGF receptor; VEGF

Indexed keywords

INSULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN A;

ACUTE DISEASE; ADULT; ARTICLE; BIOMETRY; BLURRED VISION; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE EXAMINATION; EYE REFRACTION; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RETINA MACULA LUTEA; BLOOD; DIABETIC RETINOPATHY; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PATHOPHYSIOLOGY; RETINA MACULA EDEMA; VISUAL ACUITY;

ADULT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; INSULIN; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VISUAL ACUITY;

EID: 77954167497     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1093     Document Type: Article

References (27)

1. Herse PR. Corneal hydration control in normal and alloxan-induced diabetic rabbits. Invest Ophthalmol Vis Sci 1990; 31: 2205-2213.
2. Saito Y, Ohmi G, Kinoshita S, et al. Transient hyperopia with lens swelling at initial therapy in diabetes. Br J Ophthalmol 1993; 77: 145-148. (Pubitemid 23092499)
3. Okamoto F, Sone H, Nonoyama T, Hommura S. Refractive changes in diabetic patients during intensive glycaemic control. Br J Ophthalmol 2000; 84: 1097-1102.
4. Giusti C. Transient hyperopic refractive changes in newly diagnosed juvenile diabetes. Swiss Med Wkly 2003; 133: 200-205. (Pubitemid 36636990)
5. Tai MC, Lin SY, Chen JT, et al. Sweet hyperopia: refractive changes in acute hyperglycemia. Eur J Ophthalmol 2006; 16: 663-666.
6. Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515. (Pubitemid 24379629)
7. Poulaki V, Qin W, Joussen AM, et al. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 2002; 109: 805-815. (Pubitemid 34263157)
8. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001; 280: C1358-C1366. (Pubitemid 32553190)
9. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22. (Pubitemid 29038270)
10. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-10461.
11. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795-8800.
12. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709.
13. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324-328.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31: S55-S60.
15. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179.
16. Coggins M, Lindner J, Rattigan S, et al. Physiologic hyperinsulinemia enhances human skeletal perfusion by capillary recruitment. Diabetes 2001; 50: 2682-2690.
17. Anfossi G, Russo I, Doronzo G, Trovati M. Relevance of the vascular effects of insulin in the rationale of its therapeutical use. Cardiovasc Hematol Disord Drug Targets 2007; 7: 228-249.
18. Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000; 7: 650-656.
19. Lim HS, Blann AD, Chong AY, et al. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004; 27: 2918-2924.
20. Kakizawa H, Itoh M, Itoh Y, et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004; 53: 550-555.
21. Ashraf A, Mick G, Meleth S, et al. Effect of insulin on plasma vascular endothelial growth factor in children with new-onset diabetes. J Clin Endocrinol Metab 2005; 90: 4920-4923.
22. Malamitsi-Puchner A, Sarandakou A, Tziotis J, et al. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus. Pediatr Res 1998; 44: 873-875.
23. Dullaart RP, Oomen PH, Sluiter WJ. Circulating vascular endothelial growth factor is unaffected by acute hyperglycemia and hyperinsulinemia in type 1 diabetes mellitus. Eur J Intern Med 2007; 18: 193-195.
24. Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51: 1574-1580.
25. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993-997.
26. Gehlbach P, Demetriades AM, Yamamoto S, et al. Periocular transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 2003; 14: 129-141.
27. Ideno J, Mizukami H, Kakehashi A, et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med 2007; 19: 75-79.